A major goal of our research is to improve and accelerate the therapy of our patients.
Biochemical, genetic, and neuropsychological measurement data as well as functional imaging markers of experimental interventions are identified and validated in clinical and translational studies, and successful concepts are translated into clinical practice.
For example, markers for early therapy response under antidepressant medication were identified.
Based on this, we want to establish clinical standards that predict the later response to therapy and enable the selection of optimal medication for the individual patient.
The following working groups deal intensively with the topic of therapy response ans therapy response prediction in different projects:
- Wiegand HF, Saam J, Marschall U, Chmitorz A, Kriston L, Berger M, Lieb K, Hölzel LP (2020). Challenges in the transition from in-patient to out-patient treatment in depression—an analysis of administrative health care data from a large German health insurer. Dtsch Arztebl Int. 117
- Wagner S, Kayser S, Engelmann J, Schlicht KF, Dreimüller N, Tüscher O, Müller-Dahlhaus F, Braus DF, Tadić A, Neyazi A, Frieling H, Lieb K (2019). Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions in patients with major depressive disorder. World J Biol Psychiatry 20: 519-530
- Lieb K, Dreimüller N, Wagner S, Schlicht K, Falter T, Neyazi A, Müller-Engling L, Bleich S, Tadić A, Frieling H (2018). BDNF plasma levels and BDNF exon IV promoter methylation as predictors for antidepressant treatment response. Front Psychiatry. 9: 511
- Reinhardt S, Stoye N, Luderer M, Kiefer F, Schmitt U, Lieb K, Endres K (2018) Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks. Sci Rep. 8:1329
- Wagner S, Helmreich I, Wollschläger D, Meyer K, Kaaden S, Reiff J, Roll SC, Braus D, Tüscher O, Müller-Dahlhaus F, Tadić A, Lieb K (2018). Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder. PLoS One13(4): e0194574
- Wagner S, Engel A, Engelmann J, Herzog D, Dreimüller N, Müller MB, Tadić A, Lieb K (2017). Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. J Psychiatr Res 94:96-106
- Wagner S, Tadić A, Roll SC, Engel A, Dreimüller N, Engelmann J, Lieb K (2017). A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depressive Disorders. J Affect Disord 221: 184-191
- Nicod J, Wagner S, Vonberg F, Bhomra A, Schlicht KF, Tadic A, Mott R, Lieb K, Flint J (2016) .The Amount of Mitochondrial DNA in Blood Reflects the Course of a Depressive Episode. Biol Psychiatry 80: e41-e42
- Tadić A, Müller-Engling L, Schlicht KF, Kotsiari A, Dreimüller N, Kleimann A, Bleich S, Lieb K, Frieling H (2014). Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol Psychiatry 19: 281-283
- Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tüscher O, Fellgiebel A (2014). Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology. 83(21):1930-5
- German Research Foundation (DFG)
- Federal Ministry of Education and Research (BMBF)